Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

19.37 +0.19 (+0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 873,347
Open 18.98
Bid (Size) 19.01 (10)
Ask (Size) 19.55 (1)
Prev. Close 19.18
Today's Range 18.66 - 19.43
52wk Range 14.17 - 34.13
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
Via The Motley Fool
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire

Performance

YTD
-35.4%
-35.4%
1 Month
+5.8%
+5.8%
3 Month
-8.8%
-8.8%
6 Month
+3.1%
+3.1%
1 Year
-13.2%
-13.2%

More News

Read More
Why NovoCure Stock Skyrocketed This Week
Via The Motley Fool
Topics Earnings Stocks
Exposures Financial US Equities
Why NovoCure Stock Leaped 4% Higher Today
Via The Motley Fool
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
Via Benzinga
Topics World Trade
Exposures Tariff
Earnings Scheduled For April 24, 2025
Via Benzinga
NovoCure's Earnings: A Preview
Via Benzinga
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Via The Motley Fool
Earnings Scheduled For February 27, 2025
Via Benzinga
NovoCure Surpasses Q1 Expectations
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Novocure Reports First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Why NovoCure Stock Was Withering on Wednesday
Via The Motley Fool
Novocure to Report First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
From Novocure
Via Business Wire
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
Via Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
Via The Motley Fool
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
Via Benzinga
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
From Novocure
Via Business Wire
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire

Frequently Asked Questions

Is NovoCure Limited - Ordinary Shares publicly traded?
Yes, NovoCure Limited - Ordinary Shares is publicly traded.
What exchange does NovoCure Limited - Ordinary Shares trade on?
NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NovoCure Limited - Ordinary Shares?
The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
What is the current price of NovoCure Limited - Ordinary Shares?
The current price of NovoCure Limited - Ordinary Shares is 19.37
When was NovoCure Limited - Ordinary Shares last traded?
The last trade of NovoCure Limited - Ordinary Shares was at 05/28/25 04:00 PM ET
What is the market capitalization of NovoCure Limited - Ordinary Shares?
The market capitalization of NovoCure Limited - Ordinary Shares is 2.01B
How many shares of NovoCure Limited - Ordinary Shares are outstanding?
NovoCure Limited - Ordinary Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.